Parabilis Medicines Inc (PBLS) FinancialsPBLSFinancialParabilis Medicines Inc

Evaluating the bottom line, Parabilis Medicines Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -34382.43%, while the net margin is -35447.97%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively PBLS converts its operational activities into shareholder value.

In the context of the broader market, PBLS competes directly with industry leaders such as ACAD and AMLX. With a market capitalization of $4.58B, it holds a significant position in the sector. When comparing efficiency, PBLS's gross margin of 100.00% stands against ACAD's 90.81% and AMLX's N/A. Such benchmarking helps identify whether Parabilis Medicines Inc is trading at a premium or discount relative to its financial performance.

Parabilis Medicines reported total revenue of $148,000 in Q2 2026, with a gross margin of 100%, indicating that they are beginning to generate revenue from their operations after previous quarters of zero revenue. However, they continue to face significant net losses, with a net income of -$66,955,000 in the same quarter.